Clinical Trials Logo
  1. Home
  2. Germ Cell Tumor
  3. NCT01966913

Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors — TAXIFIII  

Germ Cell Tumor Clinical Trial

Official title:
Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors - A Phase I-II Sequential Chemotherapy Protocol of Bevacizumab (Avastin) Plus High-dose ICE (Ifosfamide - Carboplatin - Etoposide) Intensification

Clinical Trial Summary

High-dose chemotherapy with autologous hematopoietic stem-cell transplantation is a standard salvage treatment used in adults with germ cell tumors (Einhorn et al, J Clin Oncol 2007).

Disease prognosis following 1 to 2 intensified combinations of etoposide - carboplatin +/- ifosfamide depends on the patient's performance status (PS) at inclusion and the prior sensitivity of the disease to cisplatin. A poor PS and/or being refractory to cisplatin suggest a higher toxicity and a bad prognosis.

However, predictive factors of response to high-dose chemotherapy do not include a chemo-sensitivity phase with a semi-intensive chemotherapy excluding a platinum compound (epirubicin - paclitaxel), which still allows stem-cell harvest. The use of this chemotherapy combination induced a response in more than one third of the patients treated during disease progression in the TAXIF I study. The same strategy was tested in the TAXIF II study, which completed the inclusion of 45 patients and was closed in May 2008. Results of the TAXIF II study, are currently being analyzed; they support the hypothesis to prioritarily treat patients with a sensitive relapsed disease at the time of the high-dose administration.

A combination of a semi-intensive sequential ICE type chemotherapy plus bevacizumab was used on a highly refractory patient. A 5 months nearly complete response was achieved. Indeed, the overexpression of VEGF (Vascular Endothelial Growth Factor) has been identified as an independent risk factor in patients with germ cell tumor. Therefore, a treatment strategy using an inductive chemotherapy followed, in case of response, by a double intensification therapy in combination with a VEGF treatment, could be an interesting approach in patients with poor prognosis germ cell tumors.

The aim of this phase I/II trial is to assess the feasibility of a Bevacizumab - ICE (Ifosfamide-Carboplatin-Etoposide) high dose combination with the support of autologous hematopoietic stem cell for two intensive consecutive cycles ("tandem" intensification) in patients with a poor prognosis germ cell tumor non refractory to a front-line mobilization chemotherapy using two half intensified consecutive combinations of Epirubicin-Paclitaxel.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01966913
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Frédéric SELLE, MD
Phone 33 1 56 01 64 52
Email frederic.selle@tnn.aphp.fr
Status Recruiting
Phase Phase 1/Phase 2
Start date April 2012
Completion date September 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06133543 - Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer N/A
Terminated NCT00369291 - CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant Phase 1
Terminated NCT00198172 - Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors Phase 2
Recruiting NCT05874063 - Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors Phase 3
Completed NCT03194906 - Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors Phase 2
Completed NCT01466231 - Everolimus in Refractory Testicular Germ Cell Cancer Phase 2
Recruiting NCT04791228 - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Phase 2
Active, not recruiting NCT03418844 - Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy N/A
Recruiting NCT05889585 - Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated With High-dose Chemotherapy and Autologous Stem Cell Transplant
Recruiting NCT05394675 - A Study of DS-9606a in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT03067181 - Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Phase 3
Withdrawn NCT03960151 - Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy Phase 2
Active, not recruiting NCT03158064 - Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Phase 2
Completed NCT03950830 - Disulfiram and Cisplatin in Refractory TGCTs. Phase 2
Recruiting NCT00898755 - Collecting and Storing Tissue From Young Patients With Cancer
Recruiting NCT04804007 - Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT Phase 2
Terminated NCT02988843 - Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors Phase 2
Recruiting NCT05259605 - Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Active, not recruiting NCT03638167 - EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors Phase 1
Recruiting NCT04308330 - Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies Phase 1